Abstract
Background
Medically prescribed diacetylmorphine, the active ingredient of heroin, has been shown to be effective for the treatment of severe opioid addiction. However, there are no data regarding its effectiveness among Aboriginal heroin injectors.
Methods
The present analyses were performed using data from the NAOMI study (North American Opiate Maintenance Initiative), an open-label randomized controlled trial that compared the effectiveness of injectable diacetylmorphine (45.8%) and hydromorphone (10%) vs. oral methadone (44.2%) among long-term treatment-refractory opioid-dependent individuals. Rates of retention and response to treatment were analyzed among participants from the Vancouver site (n=192).
Results
Baseline profiles were similar among Aboriginal (n=60) and non-Aboriginal (n=132) participants except for higher HIV positive rates among Aboriginal people (23.3% vs. 8.3%). Among Aboriginal participants in the injection and methadone groups, retention rates at 12 months were 84.4% vs. 57.1% and response rates were 68.8% vs. 53.4%, respectively. Aboriginal and non-Aboriginal rates were not significantly different.
Discussion
Offering treatment assisted with medically prescribed diacetylmorphine or hydromorphone to long-term treatment-refractory opioid-dependent Aboriginal people could be an effective way to attract them into and retain them in treatment as well as dramatically reduce the risk of HIV infection.
Key words: Aboriginal, Canada, pioid-dependence, substitution treatment, diacetylmorphine, injectable, hydromorphone, injectable, methadone, oral
Résumé
Contexte
Prescrite à des fins médicales, la diacétylmorphine, ingrédient actif de l’héroïne, a prouvé son efficacité dans le traitement de la dépendance sévère aux opiacés. Cependant, il n’existe pas de données sur son efficacité chez les héroïnomanes autochtones.
Méthode
Nos analyses ont été effectuées à l’aide des données de l’étude NAOMI (North American Opiate Maintenance Initiative), un essai ouvert randomisé et contrôlé qui compare l’efficacité de la diacétylmorphine injectable (45,8 %) et de l’hydromorphone (10 %) au traitement oral à la méthadone (44,2 %) chez les opiomanes réfractaires aux traitements prolongés. Nous avons analysé les taux de maintien et de réponse au traitement chez les participants de l’étude à Vancouver (n=192).
Résultats
Les profils de référence des participants autochtones (n=60) et non autochtones (n=132) étaient semblables, à l’exception du taux de séropositivité VIH, plus élevé chez les Autochtones (23,3 % c. 8,3 %). Parmi les participants autochtones des groupes du traitement par injection et du traitement à la méthadone, les taux de maintien après 12 mois étaient de 84,4 % et de 57,1 %, et les taux de réponse étaient de 68,8 % et de 53,4 %, respectivement. Les taux pour les Autochtones n’étaient pas significativement différents des taux pour les Non-Autochtones.
Discussion
Offrir aux opiomanes autochtones réfractaires aux traitements prolongés un traitement assisté par la diacétylmorphine prescrite à des fins médicales ou par l’hydromorphone pourrait être un moyen efficace de les attirer vers les centres de traitement et de réduire considérablement leurs risques de contracter des infections à VIH.
Mots clés: Autochtones, Canada, dépendance aux opiacés, thérapie de substitution, diacétylmorphine injectable, hydromorphone injectable, méthadone, voie orale
Footnotes
Acknowledgements: The NAOMI trial was funded through an operating grant from the Canadian Institutes of Health Research with additional support from the Canada Foundation for Innovation, the Canada Research Chairs Program, the University of British Columbia, Providence Health Care, the University of Montreal, Centre de Recherche et Aide aux Narcomanes, the Government of Quebec, Vancouver Coastal Health Authority and the BC Centre for Disease Control. The authors acknowledge the dedication of N. Laliberté, C. Gartry, K. Sayers, P-A Guevremont, P. Schneeberger, J. Chettiar, K. Lock, J. Lawlor, P. Pelletier, S. Maynard, M-I. Turgeon, G. Brunelle, A. Chan, S. MacDonald, T. Corneil, J. Geller, S. Jutha, S. Chai, M. Piacsezna, S. Sizto, the many remaining staff and members of the DSMB (A. Marlatt, N. El-Guebaly, J. Raboud, D. Roy). The authors also recognize the many US and Canadian (J. Rehm, B. Fischer) scientists who contributed to the early design discussions but ultimately were unable to participate in the trial. Most importantly, the authors acknowledge and thank the NAOMI trial participants.
Funding: The study is funded by the Canadian Institutes of Health Research (CIHR).
Conflict of Interest: None to declare.
References
- 1.Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr. 2002;31:237–42. doi: 10.1097/00126334-200210010-00015. [DOI] [PubMed] [Google Scholar]
- 2.Termorshuizen F, Krol A, van Prins M, Ameijden EJ. Long-term outcome of chronic drug use: The Amsterdam Cohort Study among Drug Users. Am J Epidemiol. 2005;161:271–79. doi: 10.1093/aje/kwi035. [DOI] [PubMed] [Google Scholar]
- 3.Brugal MT, Domingo-Salvany A, Puig R, Barrio G G d, Olalla P d l, Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction. 2005;100:981–89. doi: 10.1111/j.1360-0443.2005.01089.x. [DOI] [PubMed] [Google Scholar]
- 4.van den Brink W, Hendriks VM, Blanken P, van Koeter MW, van Zwieten BJ, Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ. 2003;327:310. doi: 10.1136/bmj.327.7410.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet. 2001;358:1417–23. doi: 10.1016/S0140-6736(01)06529-1. [DOI] [PubMed] [Google Scholar]
- 6.March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31:203–11. doi: 10.1016/j.jsat.2006.04.007. [DOI] [PubMed] [Google Scholar]
- 7.Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroinassisted treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry. 2007;191:55–62. doi: 10.1192/bjp.bp.106.026112. [DOI] [PubMed] [Google Scholar]
- 8.Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777–86. [DOI] [PMC free article] [PubMed]
- 9.PHAC. HIV/AIDS Epi Update. 2006. HIV/AIDS Among Aboriginal Peoples in Canada: A continuing concern. [Google Scholar]
- 10.Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend. 2005;80:329–35. doi: 10.1016/j.drugalcdep.2005.05.002. [DOI] [PubMed] [Google Scholar]
- 11.Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C, et al. Scientific and political challenges in North America’s first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI Study. Clinical Trials. 2009;6:261–71. doi: 10.1177/1740774509105222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, et al. The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America’s First Trial of Heroin-Assisted Treatment. J Urban Health 2008;85:812–25. [DOI] [PMC free article] [PubMed]
- 13.Health Canada. Best practices in methadone maintenance treatment. Ottawa, ON: Minister of Public Works and Government Services Canada; 2002. [Google Scholar]
- 14.Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 1995;1:208–10. doi: 10.1159/000259089. [DOI] [Google Scholar]
- 15.Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009;170:783–92. [DOI] [PubMed]
- 16.Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 2003;168:19–24. [PMC free article] [PubMed]
- 17.Gowing L, Farrell M, Bornemann R, Ali R. Cochrane Database Syst Rev. 2004. Substitution treatment of injecting opioid users for prevention of HIV infection. [DOI] [PubMed] [Google Scholar]